Population pharmacokinetic analysis of a novel muscarinic receptor antagonist, imidafenacin, in healthy volunteers and overactive bladder patients.

Abstract:

:The objectives of this study were to develop a population pharmacokinetic model of imidafenacin and to explore the factors that affect the pharmacokinetics of imidafenecin. A total of 2406 plasma samples were collected from 90 healthy volunteers and 457 patients with overactive bladder. We determined the plasma concentrations of imidafenacin by liquid chromatography with tandem mass spectrometry; resultant data were analyzed by a population approach using NONMEM software. The imidafenacin plasma concentration time course was described using a two-compartment model with first-order absorption and lag time. The robustness of the population pharmacokinetic model was evaluated by bootstrap resampling. The results of the population pharmacokinetic analysis demonstrated that oral clearance was decreased with advancing age, increasing hepatic function parameters (AST and ALP), food intake, and itraconazole coadministration, while the first-order absorption rate constant was decreased with food intake. All parameter estimates from the final model fell within 20% of the bootstrapped mean. In conclusion, we developed a population pharmacokinetic model for imidafenacin that well-described plasma concentration profiles. We also identified the factors affecting imidafenacin pharmacokinetics.

authors

Ohno T,Nakade S,Nakayama K,Kitagawa J,Miyabe H,Konomi T,Miyata Y

doi

10.2133/dmpk.23.456

subject

Has Abstract

pub_date

2008-01-01 00:00:00

pages

456-63

issue

6

eissn

1347-4367

issn

1880-0920

pii

JST.JSTAGE/dmpk/23.456

journal_volume

23

pub_type

杂志文章
  • Drug-induced idiosyncratic hepatotoxicity: prevention strategy developed after the troglitazone case.

    abstract::Troglitazone induced an idiosyncratic, hepatocellular injury-type hepatotoxicity in humans. Statistically, double null genotype of glutathione S-transferase isoforms, GSTT1 and GSTM1, was a risk factor, indicating a low activity of the susceptible patients in scavenging chemically reactive metabolites. CYP3A4 and CYP2...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章,评审

    doi:10.2133/dmpk.dmpk-10-rv-090

    authors: Ikeda T

    更新日期:2011-01-01 00:00:00

  • Effect of nuclear receptor downregulation on hepatic expression of cytochrome P450 and transporters in chronic hepatitis C in association with fibrosis development.

    abstract::Analysis of mRNAs from liver biopsy samples of patients with chronic hepatitis C revealed that the levels of nuclear receptor expression were correlated with those of drug-metabolizing enzymes and transporters in relation to the development of fibrosis. Overall, the median mRNA level was largely dependent on fibrosis ...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.2133/dmpk.dmpk-11-rg-077

    authors: Hanada K,Nakai K,Tanaka H,Suzuki F,Kumada H,Ohno Y,Ozawa S,Ogata H

    更新日期:2012-01-01 00:00:00

  • Association of hemoglobin levels, CYP3A5, and NR1I3 gene polymorphisms with tacrolimus pharmacokinetics in liver transplant patients.

    abstract::Tacrolimus is a widely used immunosuppressant after organ transplantation. The narrow therapeutic window and individual variability in tacrolimus pharmacokinetics make management of this agent a great challenge. This study was undertaken to determine the association of clinical markers, cytochrome P450, family 3, subf...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.2133/dmpk.dmpk-13-rg-095

    authors: Chen D,Guo F,Shi J,Zhang C,Wang Z,Fan J,Peng Z

    更新日期:2014-01-01 00:00:00

  • Rapid stimulating effect of the antiarrhythmic agent amiodarone on absorption of organic anion compounds.

    abstract::In a clinical setting, changes in pharmacokinetics due to drug-drug interactions can often directly affect the therapeutic safety and efficacy of drugs. Recently, interest has been shown in drug-drug interactions in the intestine. It is now recognized that changes in the functions of drug transporters substantially in...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.2133/dmpk.dmpk-12-rg-010

    authors: Segawa M,Ogura J,Seki S,Itagaki S,Takahashi N,Kobayashi M,Hirano T,Yamaguchi H,Iseki K

    更新日期:2013-01-01 00:00:00

  • Detection of CYP2D6 polymorphism using Luminex xTAG technology in autism spectrum disorder: CYP2D6 activity score and its association with risperidone levels.

    abstract::CYP2D6 is involved in the biotransformation of a large number of drugs, including risperidone. This study was designed to detect CYP2D6 polymorphisms with a Luminex assay, including assessment the relationship of CYP2D6 polymorphisms and risperidone plasma concentration in autism spectrum disorder children (ASD) treat...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.1016/j.dmpk.2016.01.005

    authors: Vanwong N,Ngamsamut N,Hongkaew Y,Nuntamool N,Puangpetch A,Chamnanphon M,Sinrachatanant A,Limsila P,Sukasem C

    更新日期:2016-04-01 00:00:00

  • Numerical analysis of apparent decitabine uptake in HCT116 cells: Incorporation of a bidirectional first-order kinetic parameter for ENT1 transport and Michaelis-Menten parameters for subsequent phosphorylation.

    abstract::Decitabine (DAC), a DNA methylation inhibitor, is transported into cancer cells mainly via equilibrative nucleoside transporter 1 (ENT1) and subsequently phosphorylated by deoxycytidine kinase (dCK). We previously reported that apparent DAC uptake into cells may be described using a simple compartment model with clear...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.1016/j.dmpk.2019.10.002

    authors: Ueda K,Nakamura T,Tanaka S,Hosokawa M,Iwakawa S,Ogawara KI

    更新日期:2020-02-01 00:00:00

  • Role and relevance of PEPT2 in drug disposition, dynamics, and toxicity.

    abstract::Pept2 knockout mice are an important tool to evaluate the evolving role and relevance of this proton-coupled oligopeptide transporter beyond drug disposition, where the transporter also modulates the pharmacodynamic and toxicodynamic effects of drug substrates. Our in vivo studies with glycylsarcosine in Pept2 knockou...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章,评审

    doi:10.2133/dmpk.23.236

    authors: Kamal MA,Keep RF,Smith DE

    更新日期:2008-01-01 00:00:00

  • Quantitative investigation of hepatobiliary transport of [11C]telmisartan in humans by PET imaging.

    abstract::The pharmacokinetics of telmisartan are nonlinear within the clinical dose range. To identify the underlying mechanism of this nonlinearity, we conducted a PET study in healthy subjects using [11C]telmisartan. Eight healthy male subjects were enrolled in a 2-way crossover study. PET imaging was performed after intrave...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 临床试验,杂志文章

    doi:10.1016/j.dmpk.2019.02.004

    authors: Maeda K,Ohnishi A,Sasaki M,Ikari Y,Aita K,Watanabe Y,Kusuhara H,Sugiyama Y,Senda M

    更新日期:2019-10-01 00:00:00

  • The regulation mechanism of AhR activated by benzo[a]pyrene for CYP expression are different between 2D and 3D culture of human lung cancer cells.

    abstract::Most of cytochrome P450 (CYP) expressions are regulated by nuclear receptors. The regulation pathways of transcription are activated by binding of the ligand to the receptor. Many combination of CYPs and nuclear receptors in transcriptional regulation have been reported. However, we have reported that the combination ...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.1016/j.dmpk.2018.04.002

    authors: Terashima J,Jimma Y,Jimma K,Hakata S,Yachi M,Habano W,Ozawa S

    更新日期:2018-08-01 00:00:00

  • The population genetics of pharmacogenomics VIP variants in the Sherpa population.

    abstract::Polymorphic distributions of pharmacogenes among some ethnicities are under-represented in current pharmacogenetic research. Particularly, there is a paucity of pharmacogenetic information in the Sherpa population in Tibet. We used the Sequenom MassARRAY single nucleotide polymorphism (SNP) genotyping technology to de...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.1016/j.dmpk.2015.11.007

    authors: Wang L,Ren Y,Shi X,Yuan D,Liu K,Geng T,Li G,Kang L,Jin TB

    更新日期:2016-02-01 00:00:00

  • A physiologically based pharmacokinetic model characterizing mechanism-based inhibition of CYP1A2 for predicting theophylline/antofloxacin interaction in both rats and humans.

    abstract::Clinical studies have revealed that some fluoroquinolones may cause severe adverse effects when co-administered with substrates of CYP1A2. Our previous study showed antofloxacin (ATFX) was responsible for mechanism-based inhibition (MBI) of the metabolism of phenacetin in rats. In the clinical setting, ATFX is likely ...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.2133/dmpk.dmpk-10-rg-126

    authors: Pan X,Wang P,Hu N,Liu L,Liu X,Xie L,Wang G

    更新日期:2011-01-01 00:00:00

  • Association of ABCB1 polymorphisms with the antiemetic efficacy of granisetron plus dexamethasone in breast cancer patients.

    abstract::Resistance to antiemetic treatment with 5-hydroxytryptamine 3 receptor antagonists is a problem, with 20-30% of patients showing unsatisfactory responses. Efflux transport by P-glycoprotein, encoded by the ATP-binding cassette ABCB1 gene in the blood-brain barrier, has been the suggested resistance mechanism. We evalu...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.2133/dmpk.dmpk-12-rg-084

    authors: Tsuji D,Kim YI,Nakamichi H,Daimon T,Suwa K,Iwabe Y,Hayashi H,Inoue K,Yoshida M,Itoh K

    更新日期:2013-01-01 00:00:00

  • Decreased expression of intestinal P-glycoprotein increases the analgesic effects of oral morphine in a streptozotocin-induced diabetic mouse model.

    abstract::Morphine is one of the strongest analgesics and is commonly used for the treatment of chronic pain. The pharmacokinetic properties of morphine are, in part, modulated by P-glycoprotein (P-gp). We previously reported that intestinal P-gp expression levels are influenced via the activation of inducible nitric oxide synt...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.2133/dmpk.dmpk-11-rg-051

    authors: Nawa A,Fujita-Hamabe W,Kishioka S,Tokuyama S

    更新日期:2011-01-01 00:00:00

  • Population pharmacokinetic and exposure-response analyses of guanfacine in Japanese pediatric ADHD patients.

    abstract::Guanfacine hydrochloride extended-release tablet (GXR) is approved for child and adolescent patients with attention-deficit/hyperactivity disorder (ADHD). The aims of this study were to develop a population pharmacokinetic model of guanfacine after administration of GXR and to evaluate factors influencing the pharmaco...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.1016/j.dmpk.2019.07.001

    authors: Tsuda Y,Matsuo Y,Matsumoto S,Wajima T

    更新日期:2019-12-01 00:00:00

  • Paroxetine decreased plasma exposure of glyburide partly via inhibiting intestinal absorption in rats.

    abstract::Accumulating evidences have shown that diabetes is often accompanied with depression, thus it is possible that oral antidiabetic agent glyburide and antidepressive agent paroxetine are co-administered in diabetic patients. The aim of this study was to assess interactions between glyburide and paroxetine in rats. Effec...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.1016/j.dmpk.2015.02.004

    authors: Jiang S,Zhao W,Chen Y,Zhong Z,Zhang M,Li F,Xu P,Zhao K,Li Y,Liu L,Liu X

    更新日期:2015-06-01 00:00:00

  • Metabolism of selegiline hydrochloride, a selective monoamine b-type inhibitor, in human liver microsomes.

    abstract::The participation of cytochrome P-450 (CYP) isoforms in the metabolism of selegiline was investigated. Experiments using recombinant CYP isoforms expressed in human lymphoblastoid cells showed CYP2B6 to be the major CYP isoform involved with the metabolism of selegiline. CYP1A2 and CYP3A4 also contributed to the metab...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.2133/dmpk.17.199

    authors: Kamada T,Chow T,Hiroi T,Imaoka S,Morimoto K,Ohde H,Funae Y

    更新日期:2002-01-01 00:00:00

  • 6-Hydroxyindole is an endogenous long-lasting OATP1B1 inhibitor elevated in renal failure patients.

    abstract::The hepatic uptake transporter organic anion transporting polypeptide (OATP) 1B1 is inhibited by some uremic toxins; however, direct inhibition can only partially explain the delayed systemic elimination of substrate drugs in renal failure patients. This study aimed to examine the long-lasting inhibition of OATP1B1 by...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.1016/j.dmpk.2020.09.001

    authors: Masuo Y,Fujita KI,Mishiro K,Seba N,Kogi T,Okumura H,Matsumoto N,Kunishima M,Kato Y

    更新日期:2020-12-01 00:00:00

  • A summary of the current drug interaction guidance from the European Medicines Agency and considerations of future updates.

    abstract::The current EMA drug interaction guideline was published in 2012. This guideline gives important recommendations on the information required to elucidate the interaction potential of an investigational drug, both as effects of the investigational drug on the PK of other drugs and effects of other medicinal products on...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章,评审

    doi:10.1016/j.dmpk.2019.11.005

    authors: Cole S,Kerwash E,Andersson A

    更新日期:2020-02-01 00:00:00

  • Ischemia modified albumin: a novel biomarker for the detection of cardiac ischemia.

    abstract:SUMMARY:The diagnosis of cardiac ischemia remains a challenge in contemporary emergency medicine. A blood-borne biomarker is an attractive alternative to cardiac imaging or stress testing as it would be cheaper and logistically faster to obtain. A number of candidate biomarkers have been proposed for the detection of c...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.2133/dmpk.24.333

    authors: Gaze DC

    更新日期:2009-01-01 00:00:00

  • Metabolomics study on the therapeutic effect of traditional Chinese medicine Xue-Fu-Zhu-Yu decoction in coronary heart disease based on LC-Q-TOF/MS and GC-MS analysis.

    abstract::The present study aims is to investigate the metabolic mechanism of Xue-Fu-Zhu-Yu decoction (XFZYD) in the treatment of blood-stasis syndrome in Coronary Heart Disease (CHD). To that end, 30 CHD patients with Blood-Stasis Syndrome (BSS) and 20 healthy subjects were enrolled. LC-Q-TOF/MS analysis determined that in com...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.1016/j.dmpk.2019.07.004

    authors: Yi M,Li Q,Zhao Y,Nie S,Wu N,Wang D

    更新日期:2019-10-01 00:00:00

  • An analysis on distribution and inter-relationships of biomarkers under rivaroxaban in Japanese patients with non-valvular atrial fibrillation (CVI ARO 1).

    abstract::Prothrombin time (PT) has been widely used for measuring anticoagulation intensity under rivaroxaban therapy, but precise information has not been well established yet. Consecutive 96 non-valvular atrial fibrillation (NVAF) under rivaroxaban between Jan/June, 2015 were recruited. Serum concentration (SC) and PT with 5...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.1016/j.dmpk.2018.02.002

    authors: Suzuki S,Yamashita T,Kasai H,Otsuka T,Sagara K

    更新日期:2018-08-01 00:00:00

  • Human carboxylesterase isozymes: catalytic properties and rational drug design.

    abstract::Human carboxylesterase 1 (hCE-1, CES1A1, HU1) and carboxylesterase 2 (hCE-2, hiCE, HU3) are a serine esterase involved in both drug metabolism and activation. Although both hCE-1 and hCE-2 are present in several organs, the hydrolase activity of liver and small intestine is predominantly attributed to hCE-1 and hCE-2,...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章,评审

    doi:10.2133/dmpk.21.173

    authors: Imai T

    更新日期:2006-06-01 00:00:00

  • Evaluation of pharmaceutical excipients as cosolvents in 4-methyl umbelliferone glucuronidation in human liver microsomes: applications for compounds with low solubility.

    abstract::Standard incubation procedures for carrying out microsomal assays involve the use of less than 1% w/v organic solvents to minimize the potential inhibitory effects of organic solvents on metabolic activity. This presents a practical limitation for poorly soluble xenobiotics, which cannot be incubated at concentrations...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.2133/dmpk.dmpk-10-sh-086

    authors: Argikar UA,Liang G,Bushee JL,Hosagrahara VP,Lee W

    更新日期:2011-01-01 00:00:00

  • Physiologically-based modeling of monoclonal antibody pharmacokinetics in drug discovery and development.

    abstract::Over the past few decades, monoclonal antibodies (mAbs) have become one of the most important and fastest growing classes of therapeutic molecules, with applications in a wide variety of disease areas. As such, understanding of the determinants of mAb pharmacokinetic (PK) processes (absorption, distribution, metabolis...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章,评审

    doi:10.1016/j.dmpk.2018.11.002

    authors: Glassman PM,Balthasar JP

    更新日期:2019-02-01 00:00:00

  • Changes in CYP1A2 activity in humans after 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) administration using caffeine as a probe drug.

    abstract::3,4-Methylenedioxymethamphetamine (MDMA; ecstasy) is a ring-substituted amphetamine widely used for recreational purposes. MDMA is predominantly O-demethylenated in humans by cytochrome P450 (CYP) 2D6, and is also a potent mechanism-based inhibitor of the enzyme. After assessing the inhibition and recovery of CYP2D6 i...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.2133/dmpk.dmpk-12-rg-032

    authors: Yubero-Lahoz S,Pardo R,Farre M,Mathuna BÓ,Torrens M,Mustata C,Perez-Mañá C,Langohr K,Carbó ML,de la Torre R

    更新日期:2012-01-01 00:00:00

  • Genetic polymorphism of bile acid CoA: amino acid N-acyltransferase in Japanese individuals.

    abstract::In the present study, we identified three novel single nucleotide polymorphisms (SNPs), 147C>T in exon 2 (silent), 602G>C in exon 3 (Arg201Pro), and 1134C>T in exon 4 (silent), in the gene of bile acid CoA: amino acid N-acyltransferase (BAAT) by resequencing the entire coding region and the exon-intron junctions of 10...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.2133/dmpk.22.125

    authors: Tougou K,Fukuda T,Ito T,Yamazaki H,Fujio Y,Azuma J

    更新日期:2007-04-01 00:00:00

  • Five novel single nucleotide polymorphisms in the EPHX1 gene encoding microsomal epoxide hydrolase.

    abstract::Five novel single nucleotide polymorphisms (SNPs) were found in the EPHX1 gene from 96 Japanese epileptic patients. The detected SNPs were as follows: 1) SNP, MPJ6_EX1009; GENE NAME, EPHX1 ACCESSION NUMBER, NT_004525.12; LENGTH, 25 bases; 5'-CCTCACTTCAGTG/ACTGGGCTTTGCC-3'. 2) SNP, MPJ6_EX1013; GENE NAME, EPHX1; ACCESS...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.2133/dmpk.18.150

    authors: Shiseki K,Itoda M,Saito Y,Nakajima Y,Maekawa K,Kimura H,Goto Y,Saitoh O,Katoh M,Ohnuma T,Kawai M,Sugai K,Ohtsuki T,Suzuki C,Minami N,Ozawa S,Sawada J

    更新日期:2003-01-01 00:00:00

  • A randomized, placebo-controlled, single ascending-dose study to assess the safety, tolerability, pharmacokinetics, and immunogenicity of subcutaneous tralokinumab in Japanese healthy volunteers.

    abstract::Tralokinumab is a human monoclonal antibody in clinical development for asthma and atopic dermatitis that specifically neutralizes interleukin-13. This phase I, single-blind, randomized, placebo-controlled, single ascending-dose study assessed the safety, tolerability, pharmacokinetics (PK), and immunogenicity of subc...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.dmpk.2017.12.001

    authors: Baverel P,She D,Piper E,Ueda S,Yoshioka T,Faggioni R,Gevorkyan H

    更新日期:2018-06-01 00:00:00

  • Blood-brain permeability of [3H]-(3-methyl-His2)thyrotropin-releasing hormone (MeTRH) in mice: effects of TRH and its analogues.

    abstract::The present study was undertaken to characterize the transport of (3-methyl-His(2)) thyrotropin-releasing hormone ([(3)H]MeTRH) across the blood-brain barrier in mice and the effects of thyrotropin-releasing hormone (TRH) and its analogues (taltirelin and montirelin) on the transport and brain distribution. Integratio...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.2133/dmpk.18.310

    authors: Urayama A,Yamada S,Ohmori Y,Deguchi Y,Uchida S,Kimura R

    更新日期:2003-01-01 00:00:00

  • Regional difference in P-glycoprotein function in rat intestine.

    abstract::It has been reported that inhibition of the P-glycoprotein (P-gp) results in the improved absorption of P-gp substrate in the intestinal tract. In fact, the increased permeability of P-gp substrate across the intestinal epithelium was observed following inhibition of P-gp in in vitro experiments. To develop the formul...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.2133/dmpk.20.100

    authors: Iida A,Tomita M,Hayashi M

    更新日期:2005-04-01 00:00:00